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Abstract
The incidence of oral squamous cell carcinoma remains high. Oral and oro-pharyngeal carcinomas are the sixth most 
common cancer in the world. Several clinicopathological parameters have been implicated in prognosis, recurrence 
and survival, following oral squamous cell carcinoma. In this retrospective analysis, clinicopathological parameters of 
115 T1/T2 OSCC were studied and compared to recurrence and death from tumour-related causes.
The study protocol was approved by the Joint UCL/UCLH committees of the ethics for human research. The patients' 
data was entered onto proformas, which were validated and checked by interval sampling. The fields included a range 
of clinical, operative and histopathological variables related to the status of the surgical margins. Data collection also 
included recurrence, cause of death, date of death and last clinic review. Causes of death were collated in 4 categories 
(1) death from locoregional spread, (2) death from distant metastasis, (3) death from bronchopulmonary pneumonia, 
and (4) death from any non-tumour event that lead to cardiorespiratory failure.
The patients' population comprised 65 males and 50 females. Their mean age at the 1st diagnosis of OSCC was 61.7 years. Two-
thirds of the patients were Caucasians. Primary sites were mainly identified in the tongue, floor of mouth (FOM), buccal mucosa 
and alveolus. Most of the identified OSCCs were low-risk (T1N0 and T2N0). All patients underwent primary resection ± neck 
dissection and reconstruction when necessary. Twenty-two patients needed adjuvant radiotherapy. Pathological analysis 
revealed that half of the patients had moderately differentiated OSCC. pTNM slightly differed from the cTNM and showed that 
70.4% of the patients had low-risk OSCC. Tumour clearance was ultimately achieved in 107 patients. Follow-up resulted in a 3-
year survival of 74.8% and a 5-year survival of 72.2%.
Recurrence was identified in 23 males and 20 females. The mean age of 1st diagnosis of the recurrence group was 59.53 years. 
Most common oral sites included the lateral border of tongue and floor of mouth. Recurrence was associated with clinical N-
stage disease. The surgical margins in this group was evaluated and found that 17 had non-cohesive invasion, 30 had dysplasia 
at margin, 21 had vascular invasion, 9 had nerve invasion and 3 had bony invasion. Severe dysplasia was present in 37 patients. 
Tumour clearance was achieved in only 8 patients. The mean depth of tumour invasion in the recurrence group was 7.6 mm.
An interesting finding was that 5/11 patients who died of distant metastasis had their primary disease in the tongue. Nodal 
disease comparison showed that 8/10 patients who died of locoregional metastasis and 8/11 patients who died from distant 
metastasis had clinical nodal involvement. Comparing this to pathological nodal disease (pTNM) showed that 10/10 patients 
and 10/11 patients who died from locoregional and distant metastasis, respectively, had nodal disease. All patients who died 
from locoregional and distant metastasis were shown to have recurrence after the primary tumour resection.
Squamous cell carcinoma of the oral cavity has a poor overall prognosis with a high tendency to recur at the primary 
site and extend to involve the cervical lymph nodes. Several clinicopathological parameters can be employed to assess 
outcome, recurrence and overall survival.
Background
The incidence of oral squamous cell carcinoma (OSCC)
remains high [1]. Oral and oro-pharyngeal carcinomas
are the sixth most common cancer in the world [2].
Despite evolution in management, the overall survival of
patients has not improved significantly during the past 20
years, with 5-year survival rates between 45-50% [1].
Several clinicopathological parameters have been
implicated in prognosis, recurrence and survival, follow-
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year survival has been reported to vary in range accord-
ing to tumour size (T1/T2 commonly referred to as "low-
risk tumours" and T3/T4 commonly referred to as "high-
risk"). The outcome is greatly influenced by the stage of
the disease (especially pathologicalTNM) [3].
Prognosis also depends or varies with tumour primary
site, nodal involvement, tumour thickness, and the status
of the surgical margins. Moreover, the cumulative effects
of tobacco, betel nut and alcohol decrease the survival
rate [4].
In this retrospective analysis, the clinicopathological
parameters of 115 T1/T2 OSCC patients were studied
and correlated to recurrence and death from tumour-
related causes.
Methods
Identical 'intent to treat' protocols were used to treat 115
consecutive patients who presented with T1/T2 oral
squamous cell carcinoma (OSCC), (Figure 1) to the
Department of Oral and Maxillofacial Surgery, Eastman
Dental and University College Hospitals between 1992
and 2001. The study protocol was approved by the Joint
UCL/UCLH committees of the ethics for human
research.
All patients were operated upon with the primary
objective of achieving a macroscopic clearance of 0.5-1.0
cm. Postoperative radiotherapy was given according to
our standard protocols, if applicable.
The patients' data was entered onto proformas, which
were validated and checked by interval sampling. The
fields included a range of clinical, operative and histo-
pathological variables related to the status of the surgical
margins. Data collected also included recurrence, cause
of death, date of death and last clinic review. Causes of
death were collated in 4 categories (1) death from locore-
gional spread (Figures 2, 3 and 4), (2) death from distant
metastasis (Figures 5, 6 and 7), (3) death from bron-
chopulmonary pneumonia, and (4) death from any non-
tumour event that lead to cardiorespiratory failure.
Statistical analysis
The outcomes of the categorical clinicopathological vari-
ables were summarised as frequencies and percentages
for the whole group of patients and for the subgroups cat-
egorised by recurrence, 3 and 5 years survival and cause
of death. The numerical variables, "age at 1st diagnosis of
Figure 1 T1/T2 SCC of the lateral tongue.
Figure 2 Recurrence and locoregional spread-SCC of the lateral 
tongue, floor of mouth, retromolar trigone with extension to the 
lateral pharyngeal wall.
Figure 3 Recurrence and locoregional spread-exophytic SCC of 
the right face directly extended from the oropharyngeal region.
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means, standard deviations, minimal and maximal val-
ues.
Two way contingency tables were created to investigate
the relationship between the categories of the categorical
clinicopathological variables and both recurrence and
cause of death, and Fisher's exact tests were used to test
for statistical significance of the findings. Because the
expected number of patients within sub-groups was
small, the Kruskal-Wallis test was used to determine if
there was a statistically significant difference in the distri-
bution of the numerical variables, the "age at 1st diagnosis
of SCC" and "depth of invasion (mm)", for the different
categories of recurrence and cause of death.
Logistic regression, using death at the outcome of inter-
est separately for 3-year and 5-year survival was per-
formed to assess the independent effect of the numerical
and categorical covariates on the relevant outcome. A
Cox proportional hazards survival analysis was per-
Figure 4 Recurrence and locoregional spread-bilateral cervical 
lymphadenopathy of an oral cancer patient.
Figure 5 Distant metastasis-PA chest X-ray showing extensive 
cannon ball metastasis of the lungs.
Figure 6 Distant metastasis-axial chest CT showing tumour me-
tastasis to the plural spaces and parenchyma of the lungs.
Figure 7 Distant metastasis-axial upper abdominal CT showing 
multiple tumour deposits and cysts in the liver.
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covariates on survival time, measured in months. A 5%
significance level was used to assess the significance of
the hypothesis tests and the covariates in the logistic and
Cox analyses.
Results
The patient population comprised 65 males (56.5%) and
50 females (43.5%). Their mean age at the 1st diagnosis of
OSCC was 61.7 (SD5.8 years, Min 20 years, Max 96
years). Two-thirds of the patients were Caucasians
(67.8%); other prominent racial groups included Africans
(11.3%), Indians (8.7%) and Caribbeans (4.3%), (Table 1).
Primary sites were mainly identified in the tongue
(46.9%), floor of mouth (FOM) (20.9%), buccal mucosa
(9.6%) and alveolus (10.4%). Most of the identified
OSCCs were low-risk (T1N0 and T2N0) (74.8%); while
the rest had nodal disease, but no distant metastasis was
reported. All patients underwent primary resection ±
neck dissection and reconstruction when necessary.
Twenty-two patients needed adjuvant radiotherapy and 3
others adjuvant chemoradiotherapy (Table 1).
Pathological analysis revealed that half of the patients
had moderately differentiated OSCC, a quarter had well
differentiated carcinoma and only 12 patients had poorly
differentiated carcinoma (Figures 8, 9 and 10). pTNM dif-
fered somewhat from the cTNM and showed that only
70.4% of the patients had low-risk OSCC. Non-cohesive
invasion (Figures 10 and 11) was reported in 33 patients,
dysplasia at margin in 53 patients, and presence of severe
dysplasia in 72 patients (Figure 12) with a mean depth of
tumour invasion of 5.7 (SD3.8)mm (Figures 13 and 14).
Vascular invasion was evident in 28 patients (Figure 15),
while nerve invasion was identified only in 12 patients
(Figure 16). Bone and/or cartilage invasion (Figure 17)
was only present in 5 patients.
Tumour clearance (Figure 18) was ultimately achieved
in 107 (93%) patients; unfortunately, tumour recurred in
43 patients and was treated by further resection and/or
radiotherapy. Other management modalities for recur-
rent disease included chemotherapy and photodynamic
therapy. Follow-up resulted in a 3-year survival of 74.8%
and a 5-year survival of 72.2% (Table 1).
Recurrence was identified in 23 males and in 20
females, with Caucasians being the most prominent
group to report this (67.4%). The mean age of 1st diagno-
sis of the recurrence group was 59.53 years. Most com-
mon oral sites included the lateral border of tongue (15)
and floor of mouth (12). Recurrence was associated with
clinical N-stage disease in 51.2% (p < 0.001) of the
patients and pathological N-stage disease in 62.8% (p <
0.001) of the patients. Interestingly, 44.2% (p < 0.001) of
the recurrences were in moderately differentiated OSCC.
The histological sections in this group (n = 43) was evalu-
ated and found that 17 had non-cohesive invasion pattern
(p = 0.039), 30 had dysplasia at margin (p < 0.001), 21 had
vascular invasion (p < 0.001), 9 had nerve invasion (p =
0.006) and 3 had bony invasion. Severe dysplasia was
present in 37 patients (p < 0.001). Tumour clearance was
previously achieved in only 8 patients (p < 0.001). The
mean depth of tumour invasion for the recurrence group
was 7.6 (SD3.8) mm (Table 2).
Causes of death were either tumour related (i.e. locore-
gional or distant metastasis) or non-tumour related (e.g.
pneumonia or any other cause that led ultimately to car-
diorespiratory failure). An interesting finding was that 5/
11 patients who died of distant metastasis had their pri-
mary disease in the tongue (p = 0.819). Nodal disease
comparison showed that 8/10 patients who died of
locoregional metastasis and 8/11 patients who died from
distant metastasis had clinical nodal involvement (p <
0.001); (Table 3). On comparing this with pathological
nodal disease it was noted that 10/10 patients and 10/11
patients who died from locoregional and distant metasta-
sis, respectively, had nodal disease (p < 0.001). Tumour
grading showed that half of the patients (5/10) who died
from locoregional disease had poorly differentiated carci-
noma (p = 0.001); interestingly 6/11 patients who died
from metastatic disease had moderately differentiated
OSCC (p = 0.001). Patients with recurrence were margin-
ally older than non-recurrence patients (Figure 19). All
patients who died from locoregional and distant metasta-
sis were shown to have recurrence after the primary
tumour resection (p < 0.001); (Table 4). The depth of
invasion of tumour in recurrence patients was higher
than non-recurrence (Figure 20).
Further analysis of pathological variables in relation to
cause of death revealed that non-cohesive invasion is
linked to death from distant metastasis, when compared
to cohesive invasion (p = 0.002); dysplasia at margin indi-
cates poor prognosis and death from locoregional and
distant metastasis (p = 0.005), however presence of severe
dysplasia was not significantly related to tumour-related
death. Tumour capability to invade nerves and vessels
carried poor prognosis with p = 0.011 and 0.002, respec-
tively, but this was not the case with bone and cartilage
invasion (p = 0.131). The presence of positive margins,
even with subsequent radiotherapy, carried high risk of
death from locoregional and distant metastasis (p <
0.001); (Table 5); similarly, this was the case in tumour
depth of 8.6 (SD3.8)mm for locoregional spread and 9.5
(SD3.7)mm for distant spread (Table 5), (Figure 21).
Cause of death vs. patient's age revealed that older
patients are more likely to die from bronchopulmonary
pneumonia or any non-tumour sequel which results in
cardiorespiratory failure (Table 5), (Figure 22).
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Frequency (%) Frequency (%)
Gender Differentiation
Male 65 (56.5) Well 32 (27.8)
Female 50 (43.5) Moderate 60 (52.2)
Moderate-poorly 11 (9.6)
Race Poorly 12 (10.4)
Caucasian 78 (67.8)
Indian 10 (8.7) pTNM
Middle-Eastern 2 (1.7) T1N0M0 58 (50.4)
Oriental 1(0.9) T2N0M0 23 (20.0)
Other Asians 6 (5.2) T1N1M0 6 (5.2)
African 13 (11.3) T2N1M0 6 (5.2)
Caribbean 5 (4.3) T1N2aM0 6 (5.2)
T2N2aM0 9 (7.8)
Primary site T1N2bM0 1 (0.9)
Floor of mouth 24 (20.9) T2N2bM0 3 (2.6)
Tongue (lateral) 36 (31.3) T1N2cM0 2 (1.7)
Tongue (dorsal) 13 (11.3) T2N2cM0 1 (0.9)
Tongue (ventral) 5 (4.3)
Buccal mucosa 11 (9.6) Invasive front (IF)
Hard palate 3 (2.6) Cohesive 82 (71.3)
Upper alveolus 6 (5.2) Non-cohesive 33 (28.7)
Lower alveolus 6 (5.2) Dys. At Margin 53 (46.1)
Retromolar area 3 (2.6) Lymphvascular Invasion 28 (24.3)
Tuberosity 1 (0.9) Nerve Invasion 12 (10.4)
Upper lip 1 (0.9) B/C Invasion 5 (4.3)
Lower lip 5 (4.3) SD present 72 (62.6)
Neck Lump* 1 (0.9) Tumour clearance 107 (93.0)
cTNM Recurrence 43 (37.4)
T1N0M0 62 (53.9)
T2N0M0 24 (20.9) Recurrence Rx
T1N1M0 3 (2.6) Surgery 2 (1.7)
T2N1M0 5 (4.3) Surgery + radio 13 (11.3)
T1N2aM0 5 (4.3) Radio + chemo 5 (4.3)
T2N2aM0 9 (7.8) PDT 2 (1.7)
T1N2bM0 1 (0.9) Radiotherapy 21 (18.3)
T2N2bM0 3 (2.6)
T1N2cM0 3 (2.6) 3 year survival 86 (74.8)
Primary Rx 5 year survival 83 (72.2)
Surgery 90 (78.3)
Surgery + radio 22 (19.1)
Surgery + radio + chemo 3 (2.6)
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pathological variables as well as the numerical covariates
revealed that age at 1st OSCC significantly affected sur-
vival at 3-years and at 5-years (p = 0.001); grading
(pTNM) was found to be significant at 3-years (p = 0.008)
and 5-years (p = 0.025); (Table 6). Kaplan-Meir (survival)
curve is illustrated in figure 23. Cox regression analysis
reported significance in age at 1st SCC (p = 0.001; Exp B =
1.057) and grading (pTNM) (p = 0.001; Exp B = 2.914).
Discussion
The aim of surgical ablation for oral squamous cell carci-
noma is the removal of all viable tumour tissue. This intu-
itively is associated with better overall prognosis.
Occasionally despite the small tumour dimensions (as in
early disease), the actual biological characteristics of the
cancer result in residual disease despite good clearance
because of the existence of suppressed tumour clonogens
which activate after removal of the main tumour mass.
This provides some explanation as to why occasionally
indolent seeming lesions undergo massive local recur-
rence after removal of the primary lesion. Several clinico-
pathological parameters are being discussed in relation to
incidence, recurrence, disease progression and survival.
I. Gender
Oral cancer is known to affect more males than females
with an approximate ratio of 1.5:1, respectively. Nearly a
quarter of the newly diagnosed cancers in males from Sri
Lanka, India, Pakistan and Bangladesh are located in the
head and neck region [5,6]. The male:female ratio in our
study was 1.3:1. Recurrence of the disease was identified
in 23/65 males and 20/50 females.
Male patients who died from non-tumour causes were
more likely to suffer cardiorespirtory failure; while female
patients died from bronchopulmonary pneumonia (p =
0.039). The gender factor was not significant when com-
paring death from locoregional or distant metastasis.
II. Age at 1st SCC
United States (SEER) data reported that the large major-
ity of OSCC patients are over 45 years of age, with a
median age of 1st SCC diagnosis at 62 years [7].
About 6% of oral cancers occur in young people under
the age of 45 years [8]. Young age in patients with SCC of
the tongue appeared to be an independent predictor of
worse survival in another study [9], but a further study
comparing the relative survival of young people (under 45
years of age) with oral cancer compared with the survival
of older people (45 years and older) showed a higher 5
year relative survival among young people compared with
Age at 1st OSCC Depth of Invasion (mm)
Minimum 20 Minimum 1.0
Maximum 96 Maximum 18.0
Mean 61.70 Mean 5.657
*Primary site was identified before surgery and staged by cTNM, hence no T0 in the table.
Table 1: Demographic details of 115 patients with oral squamous cell carcinoma (Continued)
Figure 8 SCC grading-HE stained section low power ×25 showing 
well differentiated squamous cell carcinoma (verrucous type)as-
sociated with surface hyperkeratosis and inflammation at the ep-
ithelial stromal interface.
Figure 9 SCC grading-HE stained section viewed at low power 
×25 showing moderately differentiated squamous cellcarcinoma 
arising from surface epithelium.
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problems with appearance after cancer treatment [11].
In our study, the youngest patient was diagnosed at age
of 20 and the oldest at 96; mean diagnostic age was 61.70.
Mean recurrence age was 59.53. Age at 1st SCC is a very
significant predictor for survival at 3 and 5 years. Older
patients tend to die from cardiorespiratory failure (mean
85.20 years) and bronchopulmonary pneumonia (mean
83.83). Patients who died from distant metastasis (mean
55.82 years) are younger than those who died from
locoregional tumour spread (mean 67.70 years). Logistic
regression analysis revealed that younger patients have
worse prognosis.
III. Race
South and Southeast Asia (i.e. Sri Lanka, India, Pakistan
and Taiwan), Latin America and the Caribbean (i.e. Bra-
zil, Uruguay and Puerto Rico), Pacific regions, Eastern
Europe (i.e. Hungary, Slovakia and Slovenia) and some
parts of the Western world (i.e. France) are characterised
by high incidence rates for oral SCC [5,6].
Tongue SCC is significantly higher in Blacks compared
to Whites within the same regions of the United States.
The prevalence of oral cancer is also generally higher in
ethnic minorities in other developed countries [12,13].
A recent, interesting, oral cancer survival study com-
paring British South Asian population of South-East Eng-
land to the Non-South Asian population showed that
South Asian males have significantly better survival than
their Non-South Asian peers [14].
Figure 10 SCC grading-HE stained sections viewed at low power 
×25 showing poorly differentiated squamous cell carcinoma infil-
trating as poorly cohesive single cells and nests of tumour cells. 
There is no clear demarcation between the tumour invasion front and 
surrounding tissue.
Figure 11 Pattern of invasion. HE stained section viewed at low 
power showing moderately differentiated squamous cell carcinoma 
with cohesive invasion front. There is a clear demarcation between tu-
mour and surrounding connective tissue.
Figure 12 HE stained section ×50 magnification showing severe 
dysplasia of surface epithelium. There is an associated chronic in-
flammatory infiltrate at the interface between stroma and dysplastic 
epithelium.
Figure 13 Tumour depth-HE stained section ×100 magnification 
showing SCC at submucosal margin.
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geographic distribution of the population in the area.
Only 19 patients were from Asian background. Recur-
rence of the disease was identified in 29 Caucasians
(67.4%), 5 Indians (11.6%), 5 Africans, 2 Caribbeans
(4.7%) and 2 of other Asian origin. When comparing
patient's race and cause of death no significance was
identified. The majority of death was among Caucasians
as they represent 67.8% of the study population. An inter-
esting finding was that 3 out of the 13 African patients
died from tumour-related causes (one from locoregional
metastasis and two from distant metastasis).
IV. Primary site
The most commonly reported oral cancer sites include
the floor of the mouth (FOM) and lateral borders of the
tongue. The tongue, as a whole, is the most common (40-
50%) site for oral SCC in European and American popula-
tion. Asian population usually suffer from cancer of the
buccal mucosa due to betel quid/tobacco chewing habits;
Buccal mucosa SCC constitute 40% of OSCC in Sri
Lankan population [13].
Five-year survival is significantly reduced for more pos-
teriorly located tumours (i.e. oropharyngeal compared to
oral) [15]. Reduction in survival is largely explained by
tumour's site influence on nodal metastasis [16]. The sur-
geon's ability to achieve clear resection margins may be
restricted by accessibility to the tumour's primary site
and the need for adjuvant therapy postoperatively (i.e.
radiotherapy).
In our study, the majority of our patients suffered from
tongue cancer (n = 54) and FOM cancer (n = 24). Recur-
rence was associated with primary tumours of the tongue
(34.9%) and floor of mouth (27.9%). High association was
identified between tumour-related death and location of
primary. 7/10 dead patients from locoregional metastasis
Figure 14 Tumour depth-HE stained section ×50 magnification 
showing depth of invasion.
Figure 15 HE stained section ×100 magnification showing vascu-
lar invasion.
Figure 16 HE stained section ×100 magnification showing nerve 
invasion.
Figure 17 HE stained section ×100 magnification showing bone 
invasion.
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11 patients who died from distant disease suffered FOM
and tongue SCC; this indicates that site of primary can
predict prognosis; this can be linked to the lymphatic
drainage of these locations (via the deep cervical chains).
V. Tumour size and thickness (depth of invasion)
The tumour size usually affects choice and outcome of
treatment [15]. It also affects the surgeon's ability to
achieve complete resection, especially in deep invading
tumours. Increased tumour size has been linked to cervi-
cal involvement [16-18], high recurrence rate [16,19,20]
and poor prognosis [21,22]. However, a recent study sug-
gested that tumour size did not predict nodal disease
[23].
A precise clinically optimal tumour thickness cut-off
point has not been established [24]. The cut-off thickness
varies from centre to centre. The association of tumour
thickness with lymph node metastasis is believed to
reflect the aggressiveness of tumour growth [25].
Sixteen relevant studies were examined for the cut-off
tumour thickness points (3,4,5 and 6 mm); there was a
statistically significant difference between the 4 mm and
5 mm tumour thickness cut-off points and cervical lymph
node involvement in OSCC [24].
It has been suggested that a high relationship exists
between tumour thickness and ipsilateral cervical metas-
tasis [26-30]. The relationship between thickness of the
primary tumour and occurrence of contralateral cervical
metastasis were reported to increase by 5% in T1/T2 SCC
of the oral tongue [31]. It is now widely accepted that
thickness is more accurate predictor of sub-clinical nodal
metastasis, local recurrence and survival than tumour
size [16].
In our study, the mean tumour depth was 5.7 mm ± 3.8,
with a maximum registered depth of 18 mm. Mean depth
of invasion in disease recurrence was found to be 7.6 mm
± 3.8. Death within 3 years of diagnosis was related to
tumour depth (p = 0.043), however on further follow-up
it was found to be insignificant. Alive patients at 5 years
registered a tumour depth of invasion of 4.8 mm ± 3.5,
compared to 8.6 mm ± 3.8 for patients who died from
locoregional spread and 9.6 mm ± 3.7 for those who died
from distant disease. Tumour depth of invasion is a good
prognostic indicator.
VI. Nodal involvement and TNM system
This continues to be an interesting topic for oncology
surgeons; incidence of ipsilateral, contralateral or bilat-
eral nodal involvement has been studied. Worse progno-
sis is expected in patients with nodal disease [32]; this
worsens with the presence of extracapsular spread [33].
The incidence of occult lymph node metastasis in early
stage tumours (T1/T2) has been reported to be between
27%-40% [34-36].
Obviously, the status of ipsilateral neck is important in
assessing the risk to the contralateral neck; in one study
22% false-negatives were quoted on contralateral assess-
ment [37]; another study reported 10% [31]. Extracapsu-
lar spread was identified as an important predictor of
regional recurrence, distant metastasis, and thus, overall
survival [38].
Factors that seem to influence tumour spread to the
lymphatics include tumour primary site, thickness, dou-
ble DNA aneuploidy and poor differentiation [26,31].
Other identified factors include peri-neural invasion,
infiltrating-type invasive front and T2 tongue tumours
[29], as well as low E-cadherin for prediction of late cervi-
cal metastasis [30].
Distant metastasis was reported to occur in 5-25% of
OSCC patients [39], most commonly in uncontrolled
locoregional and N-stage diseases, especially N2/N3. Ext-
racapsular spread is a very strong predictor for systemic
spread [16,38,40].
The TNM classification of the International Union
Against cancer (UICC) relates well to the overall survival
[11,15]. The earlier the tumour stage, the better the prog-
nosis and the less complicated is the treatment [41].
There is a growing concern that TNM staging is insuffi-
cient to accurately map or classify OSCC, whose biologi-
cal impact may be related to volume and pathological
aggressiveness of disease.
Tumour diameter or surface greatest dimension is used
to indicate tumour size in the TNM system [42]; however,
this is not the most accurate when compared to tumour
thickness or depth of invasion, which can be related
directly to prognosis [[16,43-45]).
In our study, nearly 75% were diagnosed with T1/T2 N0
tumours, 8 patients had N1 disease and 21 had N2 dis-
ease. Pathological confirmation showed that 12 patients
had N1 disease and 22 patients had N2 disease. Recur-
rence was mainly associated with N-stage disease; clini-
cally 41.9% of the recurrences had N2-stage disease, while
pathologically this was evident in 44.2% of the patients.
All the patients (10/10) who died from locoregional dis-
Figure 18 HE stained section ×50 magnification showing Clear 
excision margin.
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Table 2: Demographic details of 43 patients with recurrent oral squamous cell carcinoma
Recurr. Fisher's exact 
p-values
Recurr. Fisher's exact 
p-values
Gender Differentiation
Male 23 (53.5%) Well 8 (18.6%)
Female 20 (46.5%) 0.377 Moderate 19 (44.2%)
Moderate-poorly 7 (16.3%)
Race Poorly 9 (20.9%) <0.001
Caucasian 29 (67.4%)
Indian 5 (11.6%) pTNM
Middle-Eastern 0 (0.0%) T1N0M0 10 (23.3%)
Oriental 0 (0.0%) T2N0M0 6 (14.0%)
Other Asians 2 (4.7%) T1N1M0 4 (9.3%)
African 5 (11.6%) T2N1M0 4 (9.3%)
Caribbean 2 (4.7%) 0.491 T1N2aM0 5 (11.6%)
T2N2aM0 7 (16.3%)
Primary site T1N2bM0 1 (2.3%)
Floor of mouth 12 (27.9%) T2N2bM0 3 (7.0%)
Tongue (lateral) 15 (34.9%) T1N2cM0 2 (4.7%)
Tongue (dorsal) 2 (4.7%) T2N2cM0 1 (2.3%) <0.001
Tongue (ventral) 0 (0.0%)
Buccal mucosa 2 (4.7%) IF, cohesive 26 (60.5%)
Hard palate 2 (4.7%) IF, non-cohesive 17 (39.5%) 0.039
Upper alveolus 2 (4.7%) Dys. At Margin 30 (69.8%) <0.001
Lower alveolus 3 (7.0%) Lymphvascular 
Invasion
21 (48.8%) <0.001
Retromolar area 3 (7.0%) Nerve Invasion 9 (20.9%) 0.006
Tuberosity 1 (2.3%) B/C Invasion 3 (7.0%) 0.270
Upper lip 0 (0.0%) SD present 37 (86.0%) <0.001
Lower lip 1 (2.3%) Tumour 
clearance
8 (18.6%) <0.001
Neck Lump 0 (0.0%) 0.345
Age at 1st OSCC
cTNM Mean 59.53 0.703
T1N0M0 14 (32.6%)
T2N0M0 7 (16.3%) Depth of 
Invasion (mm)
T1N1M0 1 (2.3%) Mean 7.6 <0.001
T2N1M0 3 (7.0%)
T1N2aM0 4 (9.3%)
T2N2aM0 7 (16.3%)
T1N2bM0 1 (2.3%)
T2N2bM0 3 (7.0%)
T1N2cM0 3 (7.0%) <0.001
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Cause of death Fisher's 
exact 
p-values
Alive (%) Cardio-
respiratory 
failure (%)
Pneumonia 
(%)
Regional 
met (%)
Distant 
met (%)
Total
Gender
Male 50 (60.2) 4 (80.0) 0 (0.0) 5 (50.0) 6 (54.5) 65
Female 33 (39.8) 1 (20.0) 6 (100.0) 5 (50.0) 5 (45.5) 50 0.039
Race
Caucasian 56 (67.5) 4 (80.0) 5 (83.3) 6 (60.0) 7 (63.6) 78
Indian 8 (9.6) 0 (0.0) 0 (0.0) 2 (20.0) 0 (0.0) 10
Middle-
Eastern
2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2
Oriental 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1
Other 
Asians
4 (4.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (18.2) 6
African 8 (9.6) 1 (20.0) 1 (16.7) 1 (10.0) 2 (18.2) 13
Caribbean 4 (4.8) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 5 0.914
Primary 
site
Floor of 
mouth
16 (19.3) 3 (60.0) 3 (50.0) 0 (0.0) 2 (18.2) 24
Tongue 
(lateral)
24 (28.9) 2 (40.0) 0 (0.0) 7 (70.0) 3 (27.3) 36
Tongue 
(dorsal)
10 (12.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (18.2) 13
Tongue 
(ventral)
5 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5
Buccal 
mucosa
7 (8.4) 0 (0.0) 2 (33.3) 1 (10.0) 1 (9.1) 11
Hard palate 3 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3
Upper 
alveolus
4 (4.8) 0 (0.0) 0 (0.0) 1 (10.0) 1 (9.1) 6
Lower 
alveolus
4 (4.8) 0 (0.0) 0 (0.0) 1 (10.0) 1 (9.1) 6
Retromolar 
area
2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1) 3
Tuberosity 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1
Upper lip 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1
Lower lip 5 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5
Neck Lump 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 0.819
cTNM
T1N0M0 54 (65.1) 2 (40.0) 2 (33.3) 1 (10.0) 3 (27.3) 62
T2N0M0 20 (24.1) 1 (20.0) 2 (33.3) 1 (10.0) 0 (0.0) 24
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(7/10 patients); while 10/11 patients with nodal involve-
ment died from distant metastasis, with the majority
being N2a (7/10 patients). A haematogeneous tumour
spread has been suggested with regard to the one patient
who had no nodal disease but died of distant metastasis.
Logistic regression analysis revealed that the worse the
pTNM, the worse the prognosis. TNM system is a good
indicator of tumour prognosis.
VII. Differentiation
It is widely accepted that prognosis is better in early can-
cers, particularly those that are well-differentiated
[11,15]. The WHO grading system [46] recommends 3
categories: well differentiated, moderately differentiated
and poorly differentiated. This usually depends on the
subjective assessment of the degree of keratinisation, cel-
lular and nuclear pleomorphism, and mitotic activity
[16]. The influence of histologic grading as a prognostic
factor in OSCC was assessed in 215 patients and was
found to be a significant predictor of locoregional failure
and tumour recurrence [47]. Multivariate analysis study
showed that tumour grade was significantly related to
nodal disease at the time of diagnosis [23]; however most
authorities consider this grading system as a poor indica-
tor of outcome and response to treatment [16,44,46,48].
In our study, half of the patients had moderately-differ-
entiated SCC and about 10% had poorly-differentiated
tumour. Recurrence was mainly associated with moder-
ately differentiated tumours. 9/10 patients who died of
locoregional spread had moderately, moderate-poorly
and poorly differentiated SCC; 5/9 had poorly-differenti-
ated tumour (p = 0.001). 10/11 patients who died of dis-
tant disease suffered from moderately, moderately-poorly
and poorly differentiated SCC, with 6/10 of these having
moderately-differentiated tumour (p = 0.001).
VIII. Invasive front (IF)-pattern of invasion
An extensive review of the impact of invasive front is
beyond the scope of this manuscript. The invasive front
(tumour cells at the most invasive part of the malignant
tumour) differs significantly from the central or superfi-
cial part of the tumour [49]. Understanding the biological
behaviour of these cells has lead to the link between these
cells and the risk of cervical metastasis in OSCC patients
[50]. Image and flow cytometric analysis of the invasive
front cells showed abnormal DNA content (4cER),
thereby confirming that this can give additional useful
information when selecting treatment strategies [3].
There is technical and logistic difficulty in assessing the
invasive front which if performed rigorously allowed
authorities to differentiate between epithelial dysplasia,
carcinoma in-situ and invasive cancer [11,15,16].
The pattern of invasion can be assessed by using
Anneroth et al. and Bryne et al. criteria. Grade 1 tumours
had well-delineated "pushing or cohesive" borders. In
Grade 2, the advancing edge of tumour infiltrated in solid
cords, bands or strands. Grade 3 tumours had margins
that contained small groups or cords of infiltrating cells.
In Grade 4, there is marked dissociation in small groups
or even single cells (non-cohesive) [51].
Endophytic growth pattern is associated with increased
local recurrence. High grades of infiltration (grade 3 or 4)
are usually associated with nodal involvement and subse-
quent disease metastasis; while this was not associated
with local recurrence. Pattern of invasion didn't affect
cumulative survival [51]. Another study on 68 OSCC
patients confirmed that the pattern of invasion was not
significantly related to local recurrences [52].
In our study, pathology reports showed that 33 patients
had non-cohesive pattern of invasion. In recurrence
states, non-cohesive invasion was identified in 17
patients, while cohesive fronts were evident in 26
patients. 5/33 patients with non-cohesive invasion died
from locoregional spread; while 8/33 died from distant
metastasis (p = 0.002). This suggests that non-cohesive
invasion is a significant prognostic factor associated with
distant disease [53].
IX. Presence of severe dysplasia (SD) and dysplasia at 
margin
There are variations in the pathological interpretation
and classification of dysplasia. It is widely accepted that
dysplasia precedes OSCC [54] and that 11% of OSCC
T1N1M0 3 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3
T2N1M0 2 (2.4) 1 (20.0) 1 (16.7) 1 (10.0) 0 (0.0) 5
T1N2aM0 1 (1.2) 0 (0.0) 0 (0.0) 3 (30.0) 1 (9.1) 5
T2N2aM0 0 (0.0) 1 (20.0) 1 (16.7) 2 (20.0) 5 (45.5) 9
T1N2bM0 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 1
T2N2bM0 1 (1.2) 0 (0.0) 0 (0.0) 1 (10.0) 1 (9.1) 3
T1N2cM0 2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1) 3 <0.001
Total 83 5 6 10 11
Table 3: Gender, race, primary site and cTNM vs. cause of death (Continued)
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Page 13 of 21Table 4: Differentiation, pTNM, invasive front, status of surgical margin and recurrence vs. cause of death
Cause of death Fisher's
Alive (%) Cardio-
respiratory 
failure (%)
Pneumonia 
(%)
Regional 
met (%)
Distant 
met (%)
Total
Differentiation
Well 24 (28.9) 3 (60.0) 3 (50.0) 1 (10.0) 1 (9.1) 32
Moderate 47 (56.6) 2 (40.0) 3 (50.0) 2 (20.0) 6 (54.5) 60
Moderate-poorly 8 (9.6) 0 (0.0) 0 (0.0) 2 (20.0) 1 (9.1) 11
Poorly 4 (4.8) 0 (0.0) 0 (0.0) 5 (50.0) 3 (27.3) 12 0.001
pTNM
T1N0M0 53 (63.9) 2 (40.0) 2 (33.3) 0 (0.0) 1 (9.1) 58
T2N0M0 20 (24.1) 1 (20.0) 2 (33.3) 0 (0.0) 0 (0.0) 23
T1N1M0 4 (4.8) 0 (0.0) 0 (0.0) 1 (10.0) 1 (9.1) 6
T2N1M0 2 (2.4) 1 (20.0) 1 (16.7) 2 (20.0) 0 (0.0) 6
T1N2aM0 1 (1.2) 0 (0.0) 0 (0.0) 3 (30.0) 2 (18.2) 6
T2N2aM0 0 (0.0) 1 (20.0) 1 (16.7) 2 (20.0) 5 (45.5) 9
T1N2bM0 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 1
T2N2bM0 1 (1.2) 0 (0.0) 0 (0.0) 1 (10.0) 1 (9.1) 3
T1N2cM0 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1) 2
T2N2cM0 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 <0.001
IF, cohesive 64 (78.0) 5 (6.1) 5 (6.1) 5 (6.1) 3 (3.7) 82
IF, non-cohesive 19 (57.6) 0 (0.0) 1 (3.0) 5 (15.2) 8 (24.2) 33 0.002
Dys. At Margin 33 (62.3) 1 (1.9) 2 (3.8) 8 (15.1) 9 (17.0) 53 0.005
Lymphvascular 
Invasion
13 (46.4) 1 (3.6) 2 (7.1) 6 (21.4) 6 (21.4) 28 0.002
Nerve Invasion 5 (41.7) 0 (0.0) 0 (0.0) 3 (25.0) 4 (33.3) 12 0.011
B/C Invasion 2 (40.0) 0 (0.0) 0 (0.0) 1 (20.0) 2 (40.0) 5 0.131
SD present 49 (68.1) 3 (4.2) 3 (4.2) 7 (9.7) 10 (13.9) 72 0.271
Tumour 
clearance
82 (76.6) 5 (4.7) 5 (4.7) 6 (5.6) 9 (8.4) 107 <0.001
Recurrence 19 (44.2) 2 (4.7) 1 (2.3) 10 (23.3) 11 (25.6) 43 <0.001
Total 83 5 6 10 11
patients had cancer elsewhere [55]. Field cancerisation
concept and the presence of dysplastic epithelium in can-
cerous tissue have been reported in a number of studies
[56,57].
A study on small group of patients has revealed that the
presence of mild or moderate epithelial dysplasia at the
margins of surgically removed OSCC carries a significant
risk for the development of local recurrence [58]; it is
worth noting that patients with severe dysplasia were
excluded from the study as it was believed that the
pathology overlaps with carcinoma in situ.
In this study, severe dysplasia was present in the pathol-
ogy specimens of 72 patients and dysplasia at margin was
identified in 53 patients. Recurrence was seen in 37/43
Jerjes et al. Head & Neck Oncology 2010, 2:9
http://www.headandneckoncology.org/content/2/1/9
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dysplasia at margins. Severe dysplasia was present in the
specimens of 7/10 and 10/11 patients who died from
locoregional spread and distant metastasis, respectively
(p = 0.271). Dysplasia at margin was identified in the sur-
gical resection of 8/10 and 9/11 patients who died from
locoregional spread and distant metastasis, respectively
(p = 0.005). Dysplasia at margin is an excellent predictor
of tumour spread.
X. Lymphvascular and nerve invasion
Lymphvascular and peri-/endoneural invasion show a
significant association with tumour size, histological
grading, invasive front, nodal involvement, status of the
surgical margins, overall prognosis and survival [15].
Lymphvascular invasion implies a considerable number
of tumour cells are entering the vascular compartment
which increases the likelihood of regional and distant
metastasis [16,59].
A recent study reported that a weak or limited lympho-
cyte response at the tumour/host interface is strongly
associated with local recurrence and death [53]. An
inverse relationship was also reported by other studies,
between lymphocytic infiltrate and nodal disease and
overall prognosis [60,61].
It has been proposed that tumour emboli are more dif-
ficult to form in the small-calibre lymphatics of superfi-
cial areas than in the wider lymphatics of deep tissue,
hence tumour thickness may play a vital role in lymph-
vascular invasion [24,62].
In this study, vascular invasion was reported in 28
patients. Recurrence was detected in 21/43 patients with
lymphovascular invasion. Out of 28 patients with lym-
phovascular invasion 6 died of locoregional metastasis
and 6 died of distant metastasis (p = 0.002). This indicates
that this is one of the determinant factors in prognosis.
Prognostic value of perineural invasion has been high-
lighted in several studies and linked to regional recur-
rence and distant metastasis [63,64]. Others detected no
such association [52].
In a recent multivariate analysis of perineural invasion
of small and large nerves, invasion of large nerves was
associated with local recurrence [53].
In this study, perineural invasion was reported in 12
patients. Recurrence was seen in 9/43 patients who
reported this invasion. 3/12 and 4/12 patients with lym-
phovascular invasion died from locoregional and distant
metastasis, respectively (p = 0.011). This indicates that
this is another determinant factor in prognosis.
XI. Bone/cartilage (B/C) invasion
Bone and cartilage invasion affect prognosis [11,15]. This
usually influences the type and extent of treatment [16].
Extensive work in this area has been carried out by Julia
Woolgar who suggested that T4N0 have a better progno-
sis than the other stage IV categories.
In our study, only 5 patients were reported to have inva-
sion of the mandibular cortical plate. Three of those
patients reported disease recurrence. 1/5 and 2/5 patients
with bone invasion died from locoregional and distant
metastasis, respectively (p = 0.131).
XII. Tumour clearance
The UK guidelines consider both mucosal and deep mar-
gins of 5 mm and more as clear, 1-5 mm as close and less
than 1 mm as involved [16,65]. This usually ignores the
formalin-shrinkage effect which can be at least 30% [51].
So in order to achieve a 5 mm pathological clearance, 8-
10 mm in situ surgical margin need to be taken [66].
Figure 19 Age at 1st SCC vs. recurrence.
Figure 20 Depth of tumour invasion vs. recurrence.
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local recurrence [51] and have a negative effect on sur-
vival [67,68]. Furthermore, several studies have shown
that local recurrence and overall survival benefit from
achieving negative resection margins [51,69-71].
Interestingly, a study revealed that the presence of
tumour cells within a distance of less than 5 mm, but not
into the deep surgical margin, does not necessarily
require additional treatment [52].
Despite the use of intraoperative frozen section analy-
sis, 7% of our patients had close or positive margins on
final histologic sections. This compares favourably with
the world's literature [47,72,73]. When assessing disease
recurrence, 8/43 patients had clear margins at the pri-
mary resection; this suggests high-risk surgical margins
(i.e. non-cohesive, lymphovascular involvement) and bio-
logic or genetic characteristics as the likely cause. Num-
ber of deaths in patients with locoregional and distant
metastasis exceeds the number of deaths in patients with
positive margins; this indicates that recurrence and
tumour progression are possible even when achieving
clear (tumour-free) margins [53].
XIII. Management
Currently the gold standard management is surgery.
Radiotherapy has been proposed as neo-adjuvant and
adjuvant with chemotherapy. Photodynamic therapy is
moving towards becoming the "fourth modality"; favour-
able results have been achieved in managing advanced
tumours of the head and neck, using PDT.
Patients with nodal recurrence have a significantly
worse disease free survival compared to patients without
[11,15]. Pathological extent of the metastatic disease at
the time of initial surgery tends to influence the rate of
recurrence [16,74,75]. Others include surgical interven-
tion and adjuvant therapy [38,40]. Survival is better in
Table 5: Age at 1st OSCC and depth of invasion vs. cause of death
Cause of death Kruskal wallis 
p-values
Alive at 5-
years
Cardio-
respiratory 
failure
Pneumonia Regional met Distant met
Age at 1st 
OSCC
Mean 58.73 85.20 83.83 67.70 55.82 <0.001
Std. Deviation 14.373 8.228 7.026 12.230 15.276
Std. Error 1.578 3.680 2.868 3.867 4.606
Lower Bound 
95% CI
55.60 74.98 76.46 58.95 45.56
Upper Bound 
95% CI
61.87 95.42 91.21 76.45 66.08
Minimum 20 73 73 49 34
Maximum 91 96 94 85 72
Depth of 
Invasion 
(mm)
Mean 4.837 4.000 6.300 8.620 9.545 <0.001
Std. Deviation 3.4516 1.6016 3.9085 3.8250 3.7377
Std. Error 0.3789 0.7162 1.5956 1.2096 1.1270
Lower Bound 
95% CI
4.084 2.011 2.198 5.884 7.034
Upper Bound 
95% CI
5.591 5.989 10.402 11.356 12.057
Minimum 1.0 2.5 3.2 5.5 3.3
Maximum 18.0 6.7 14.0 17.0 16.0
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Page 16 of 21patients with local recurrence versus regional recurrence
[76]. The reported mean survival following distant spread
is less than 6 months and 90% of the cases are dead by 2
years [39].
XIIIa. Surgery
Surgery continues to be the well established mode of ini-
tial definitive treatment for the majority of OSCC
patients [77]. Resection of the primary tumour is
employed with dissection and removal of the cervical
lymphatic chain, when indicated. Reconstruction of the
defect can be by locoregional repair or by distant free tis-
sue transfer. The employment of free tissue transfer com-
bined with radiotherapy has improved survival from 40%
to 70% [78].
Elective neck dissection is employed when the risk of
cervical involvement is over 15-20% [24,79,80]. Elective
neck dissection may be both diagnostic and therapeutic.
It helps in defining the status of the neck, removal of
undetectable metastasis and determines the need for
adjuvant therapy [24]. Therapeutic neck dissection is of
high benefit in patients with regional metastasis and has
also been of benefit in patients with N0 neck [81,82];
however controversies arise in patients with T1N0 dis-
ease. Aggressive adjuvant therapy has been recom-
mended for patients with extracapsular spread [38].
The most commonly used flap includes radial forearm,
mandibular fibula free flap reconstruction, deep circum-
flex iliac artery and perforators. Oral oncologic recon-
struction showed that the submental artery island flap is
simple and reliable [83]; the jejunum flap after circumfer-
ential pharyngolaryngectomy has a high success rate [84].
In this study, management of the primary tumours was
with surgery (n = 90), surgery followed by radiotherapy (n
= 22) and surgery with chemoradiotherapy (n = 3). Few of
the recurrences were treated with surgery (n = 2) and sur-
gery with radiotherapy (n = 13). Surgery involved primary
tumour resection. When there was a nodal disease, neck
dissection and free tissue transfer was employed. Man-
agement of recurrence was mainly by radiotherapy (21/
43), which was sometimes preceded by surgery (13/43).
Surgery alone was given to 2 patients.
XIIIb. Chemoradiotherapy
Radiotherapy plays a key role in the management of early-
stage and locally advanced SCC, either alone or more fre-
quently combined with surgery and/or chemotherapy
[1,85]. Postoperative radiation effect is the reason why
positive tumour margins are controlled locally [51].
The role of chemotherapy in the management of OSCC
continues to evolve. Locoregional advanced SCC can
respond to chemotherapy, as an induction or palliative
treatment, with irradiation. The current most favoured
regimens for induction chemotherapy include cisplatin/
infusional 5-fluorouracil/docetaxel [86].
Recent trials have showed that the use of concurrent
single agent chemoradiotherapy (cisplatin) lead to a clear
survival benefit of 11% [87,88].
In this study, management of the primary tumours was
with surgery followed by radiotherapy (n = 22) and sur-
gery with chemoradiotherapy (n = 3). Few of the recur-
rences were treated with surgery (n = 2) and surgery with
radiotherapy (n = 13). Most recurrences were treated
with radiotherapy (n = 21), surgery and radiotherapy (n =
13) and chemoradiotherapy (n = 5).
Figure 21 Age at 1st SCC vs. survival. (1) Alive, (2) death from any 
non-tumour event that lead to cardiorespiratory failure, (3) death from 
bronchopulmonary pneumonia, (4) death from locoregional spread, 
and (5) death from distant metastasis.
Figure 22 Depth of tumour invasion vs. survival. (1) Alive, (2) death 
from any non-tumour event that lead to cardiorespiratory failure, (3) 
death from bronchopulmonary pneumonia, (4) death from locore-
gional spread, and (5) death from distant metastasis.
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Photodynamic therapy (PDT) is a minimally invasive
method of treating a variety of tumours. The treatment
can be delivered under local or general anaesthesia, and
the delivery method includes surface illumination or
interstitial application (iPDT). This therapy can be
repeated as required as there is no cumulative toxicity; it
can also be applied before or after any of the conventional
treatment modalities. In this study, two patients with
recurrent disease underwent photodynamic therapy.
The management of patients with premalignant lesions
of the oral mucosa in "field cancerisation", with multi-
centric foci of invasion, presents a considerable problem
for the surgeon. One study reported the use of PDT to
treat 11 patients with "field cancerisation" occurring in
the oral cavity, with excellent outcome [89]. Nineteen
patients with histologically confirmed oral cancer (8 with
field change disease) and one with severe dysplasia, were
sensitized and treated with mTHPC-PDT. The results
were assessed clinically and histologically. Most patients
healed very well, but tongue tethering was seen in 1
patient and another had necrosis in normal areas due to
light scattering within the mouth [90].
A phase I-II study was conducted to assess the safety
and efficacy of iPDT for patients with persistent or recur-
rent head and neck cancer unsuitable for further treat-
ment with surgery, radiotherapy or chemotherapy,
recruited for 'last hope' salvage treatment. The results
showed that 9 patients achieved a complete response and
five are alive and free of disease 10-60 months later. The
median survival was 16 months for the 33 responders,
but only 2 months for the 12 non-responders [91].
XIV. Morbidity and mortality
True recurrence develops much earlier than metachro-
nous disease and carries the worst prognosis [16,92]. One
study reported that 20/200 patients reported true recur-
rence and 18/20 died from the disease. While only 4/15
patients died of the disease [17]. Table 2 shows that in our
study of early tumours the biology of the lesion and the
histopathology of its excision (i.e. the margin) were sig-
nificant indicators of recurrence.
To clarify the use of terms in the tables 3 and 4: we use
3-year and 5-year survivals to try and allow comparison
between patient groups. However there are problems
with the exact timing used in published studies creating a
'lead time bias' effect often which confounds analysis if
not explicitly stated, suggesting an erroneously beneficial
effect. Biologically these timing do not reflect tumour
doubling but only current medical convention and sepa-
rate timing for each specific pathology may be more valu-
able i.e. for instance 30 months survival is important in
oral squamous cell carcinoma since most recurrences
tend to occur before this time. These empirically derived
year's survival figures are however a useful rule of thumb
for quick review where 3 year survival reflects recurrence
and 5 year survival reflects the modality used and overall
pathology. In head & neck squamous cell cancer with its
usual stepwise progression, locoregional failure is an out-
come to be avoided. It is conventional wisdom that dis-
tant metastasis may have occurred at a very early stage in
tumour growth and may not have been easily identified
and managed by locoregional treatment i.e. surgery or
radiotherapy and so is conveniently de-emphasized when
comparing treatments as unavoidable, recent advances in
molecular biology has highlighted this perception as
erroneous. We also need to consider our patient popula-
Table 6: Logistic regression analysis on all the overall clinicopathological variables
3-years 5-years
odds ratios p-values odds ratios p-values
Age at 1st OSCC 1.085 0.001 1.096 0.001
Gender 5.504 0.025 3.252 0.111
Grading cTNM 0.527 0.345 0.843 0.806
Differentiation 1.111 0.794 0.994 0.990
Grading pTNM 8.012 0.008 5.707 0.025
Invasive front-invasion 0.891 0.894 1.374 0.713
Dysplasia at margin 0.361 0.259 0.244 0.130
Lymphvascular 
invasion
2.067 0.425 3.508 0.174
Nerve invasion 1.460 0.752 1.723 0.671
Tumour clearance 0.387 0.411 0.200 0.233
Recurrence 2.211 0.383 3.137 0.207
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of which have a common origin in the cancer aetiology
i.e. smoking and alcohol) which themselves have a major
impact on tumour treatment and patient survival (i.e.
hypoxia reducing radiotherapy effect or atherosclerosis
reducing anastomosis viability). This lends itself to the
statistical iteration of eliminating the effect of non-
tumour associated deaths for modality comparison; how-
ever logically and holistically this again is a conventional
often used statistical distortion since the tumour/host is
represented by one entity, the patient. It may be used to
help economic arguments when considering the cost/
benefit of treatments when results of unprocessed data
fail to produce clarity.
XV. Multidisciplinary approach and ethical considerations
Modern management of head and neck cancer is almost
universally coordinated through a multidisciplinary team.
The team consists of surgeons, medical oncologists, radi-
ation oncologists, pathologists, AHPs (Allied Health Pro-
fessionals) and radiologists. The discussions within this
group are variable in their nature and transparency. It is
not unusual for one particular group to dominate the
views of the MDT. Often, very strong views are held by
different specialties with some surgeons willing to oper-
ate on almost anyone, while radiation oncologists might
believe that a primary chemo-radiotherapeutic approach
is better for the patient. The final discussion with the
patient is similarly biased towards the speciality of the
person giving the advice and almost any decision can be
justified by saying that it is the patient's choice. However,
that is not to say that patients should not have a choice.
Their views are paramount especially if they are provided
with good quality honest information about survival rates
with different treatment approaches and issues about
quality of life.
Most research in head and neck cancer is targeted at
evaluation of new chemotherapeutic agents. To date, this
Figure 23 Kaplan Meir survival calculations per demographic and tumour factor assessed. 
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ably unrewarding. However, with pressure to recruit to
trials, patients will often be directed down the path of an
industrially funded chemotherapy trial as opposed to
being offered more conventional treatment. With man-
agement of head and neck, it has been clearly shown that
unless one gets a complete response, the patient's prog-
nosis is poor. Most drug trials talk in terms of overall
response with complete response rates being usually in
single figure percentages. So it is justifiable to question
the ethics of many drug trials in advanced head and neck
cancer.
Management of T1 disease: Most people would agree
that T1 lesions can be treated by simple excision. This
can be achieved either with a scalpel or with a laser. The
advantage of using a laser is a relatively bloodless opera-
tion and less scar tissue formation due to reduced myofi-
broblastic contraction. Photodynamic therapy has also
been used effectively in the management of T1 disease.
Management of the neck is somewhat more controver-
sial. Until recently, tumour thickness has been the most
accurate predictor of metastatic lymphadenopathy with a
cut-off at about 4-6 mm being indicative of an increased
risk of neck metastasis. This has been the basis of the
SEND trial which seeks to identify patients who benefit
from elective neck dissection in T1/early T2 disease.
Much of this has been rendered unnecessary by the use
of ultrasound investigation of the neck usually in con-
junction with ultrasound guided fine needle aspiration
cytology. This approach gives high sensitivity and speci-
ficity in evaluation of the neck. Even in the management
of the neck when a primary neck dissection is not per-
formed, interval ultrasound scanning would appear to
pick up metastatic nodal disease before extranodal spread
has occurred.
The use of very accurate surgically directed radiother-
apy in the form of brachytherapy for very early disease
may be justified in some cases i.e. where the surgical
sequelae outweigh the disadvantage of using a modality
which in essence can only be used once. We must con-
sider carefully the bystander tissue irradiation which may
have a significant adverse host effect when treating loca-
lised early cancer [93]. Very early lesions in the form of
T1/early T2 disease are more appropriately surgically
treated with an adequate margin of surgical excision with
perhaps adjunctive therapies used at the margin of the
lesion in cases of adverse histopathological features. Elec-
troporation to the margin may also be considered in
selected cases [94]. Both modalities are limited by avail-
ability and brachytherapy in particular by the additional
patient burden in the form of a period of isolation for
radiation protection purposes.
Management of T2 disease: This is even more contro-
versial. A true thin T2 lesion can probably be safely
resected but as soon as there is any increase in tumour
thickness, neck dissection would be advocated. At this
stage with thicker T2s and as well as T3 and T4, the size
of the elective surgical defect would make reconstruction
necessary. To some extent, this obviates any discussion
about the need for neck dissections as this will be incor-
porated in the management.
In summary, squamous cell carcinoma of the oral cavity
has a poor overall prognosis with a high tendency to
recur at the primary site and extend to involve the cervi-
cal lymph nodes. In this article we have discussed several
clinicopathological parameters that can be utilised to pre-
dict outcome, recurrence and overall survival.
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